Purchases of Orphan Drug to Treat Hormone Deficiency Limited

by Admin | May 23, 2013 9:57 am

May 23, 2013—The manufacturer of the only FDA-approved orphan drug for children with a rare hormone deficiency that causes short stature is limiting purchases due to an imminent halt in production.

The Office of Pharmacy Affairs (OPA) posted the notice[1] by Ipsen Biopharmaceuticals, the maker of the drug Increlex, on its website’s home page on May 22. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[2].    Already registered? Click here to login[3]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. posted the notice: http://www.hrsa.gov/opa/programrequirements/manufacturerletters/2013/ipsenletter.pdf
  2. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  3. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2013/05/purchases-of-orphan-drug-to-treat-hormone-deficiency-limited/

Copyright ©2024 340binformed.org unless otherwise noted.